Trials that use: Interim analysis / alpha spending
New to this method? Read the tutorial →
11,819 results
- Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy: Complete Statistical AnalysisIndependent statistical analysis of Study of Malaria Vaccine RTS,S/AS01E in Plasmodium Falciparum-infected and Uninfected Adults Pre-treated With Anti-malarial Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing’s Disease or Acromegaly: Complete Statistical AnalysisIndependent statistical analysis of Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Study of Mattress Type in Fibromyalgia: Complete Statistical AnalysisIndependent statistical analysis of Study of Mattress Type in Fibromyalgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01108718).
- Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring: Complete Statistical AnalysisIndependent statistical analysis of Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring: primary endpoint results, effect estimate…
- Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Study of Median Lobe Prostatic UroLift Procedure: Complete Statistical AnalysisIndependent statistical analysis of Study of Median Lobe Prostatic UroLift Procedure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02625545).
- Study of MEK162 for Children With Low-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Study of MEK162 for Children With Low-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02285439).
- Study of Mepolizumab Autoinjector in Asthmatics: Complete Statistical AnalysisIndependent statistical analysis of Study of Mepolizumab Autoinjector in Asthmatics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03099096).
- Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN): Complete Statistical AnalysisIndependent statistical analysis of Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Metoclopramide in Small Bowel Capsule Endoscopy: Complete Statistical AnalysisIndependent statistical analysis of Study of Metoclopramide in Small Bowel Capsule Endoscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01630109).
- Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting: Complete Statistical AnalysisIndependent statistical analysis of Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia: Complete Statistical AnalysisIndependent statistical analysis of Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014): Complete Statistical AnalysisIndependent statistical analysis of Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03745989).
- Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001): Complete Statistical AnalysisIndependent statistical analysis of Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01370694).
- Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery: Complete Statistical AnalysisIndependent statistical analysis of Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery:…
- Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis: Complete Statistical AnalysisIndependent statistical analysis of Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Study of Nasal Insulin to Fight Forgetfulness – Device Study: Complete Statistical AnalysisIndependent statistical analysis of Study of Nasal Insulin to Fight Forgetfulness - Device Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03857321).
- Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292): Complete Statistical AnalysisIndependent statistical analysis of Study of Nasonex® for the Treatment of Nasal Polyps in Pediatric Subjects Between Ages of 6 and Less Than 18 Years Old (P04292): primary endpoint results, effect estimate…
- Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients: Complete Statistical AnalysisIndependent statistical analysis of Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Complete Statistical AnalysisIndependent statistical analysis of Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012): Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate…
- Study of Nivolumab for Advanced Cancers in India: Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab for Advanced Cancers in India: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03444766).
- Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064): Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139): Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate…
- Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of NKTR 255 in Combination With Cetuximab in Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study of NKTR 255 in Combination With Cetuximab in Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma: Complete Statistical AnalysisIndependent statistical analysis of Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment: Complete Statistical AnalysisIndependent statistical analysis of Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment: primary endpoint results, effect estimate with confidence interval, sample-size…
- Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Study of Oral Edaravone in Healthy Adult Males: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral Edaravone in Healthy Adult Males: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04481750).
- Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002): Complete Statistical AnalysisIndependent statistical analysis of Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain: Complete Statistical AnalysisIndependent statistical analysis of Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain: primary endpoint results, effect estimate…
- Study of Panobinostat in Patients With Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study of Panobinostat in Patients With Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00985946).
- Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor: Complete Statistical AnalysisIndependent statistical analysis of Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Pazopanib and Ixabepilone in Patients With Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Study of Pazopanib and Ixabepilone in Patients With Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01012362).
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585): primary endpoint results, effect estimate with confidence interval,…
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355): primary endpoint results, effect estimate…
- Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177): primary endpoint results, effect estimate…
- Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689): Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689): primary endpoint results, effect estimate…
- Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma: Complete Statistical AnalysisIndependent statistical analysis of Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02998268).